Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020 - 411 Drugs in Clinical Pipeline, 164 Drugs in Pre-Clinical Phase & 32 Marketed Drugs - Research and Markets
DUBLIN, August 9, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020" report to their offering.
The global increase in the prevalence of cancer and the increasing recognition of the therapeutic and commercial opportunities offered by new oncology treatments have provided a major incentives for the pharmaceutical industry to pursue the development of new agents for the treatment of cancer. To tackle the ever rising global cancer burden, the cancer treatment is inclining towards the targeted drug therapy due to the numerous drawbacks associated with conventional chemotherapy. Targeted drug therapy includes targeting various signaling pathways associated to the tyrosine kinase receptors. Ample of studies have been performed which confirm their intrinsic involvement of tyrosine related pathways in development of the tumors.
Tyrosine kinases play the most critical part in the modulation of growth factor signaling. Activated forms of these enzymes can cause increases in tumor cell proliferation and growth, induce antiapoptotic effects, and promote angiogenesis and metastasis. In addition to activation by growth factors, protein kinase activation by somatic mutation is a common mechanism of tumor genesis. Because all of these effects are initiated by receptor tyrosine kinase activation, they are key targets for inhibitors.
The TKI drug discovery has evolved dramatically in recent years. Along with the launch of new drugs, efficient approaches for the development of potent and selective inhibitors with desirable properties have become established. At present kinase inhibitors are being designed from crystallography to deal with different binding modes and unexpected inhibitor induced conformational rearrangements. Much of kinase inhibitors which are supposed to enter in market in near future are rationally designed through high throughput screening and empirical optimization on the basis of structure-activity relationships. Sophisticated proteomic approaches have been developed in conjunction with panels of enzyme assays to allow for a more thorough annotation of kinase inhibitor selectivity.
Now with the considerable amount of research and advancement in technology, kinase signaling pathway is seen as the largest class of potential drug targets by the pharmaceutical industry. Over the last decades, billions have been spent and huge efforts have been taken in basic and clinical cancer research. About a decade ago, the race between drugs and cancer cells reached a new level by introduction of tyrosine kinase inhibitors into pharmacological anti-cancer therapy.
Clinical pipeline of cancer tyrosine kinase inhibitor therapeutics is quite strong due to which competitive product is expected to enter continuously in global market. Owing to increasing cancer incidences, it has become imperative to take necessary steps to introduce innovative tyrosine kinase inhibitor therapeutics in global market. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Higher cost effectiveness is expected due to which sales is expected to increase and profit margins will increase. With all these development, the future of tyrosine kinase therapeutics looks optimistic.
Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020 Report Highlights:
Introduction to Cancer Tyrosine Kinase Inhibitors
Signaling Pathway of Receptor Tyrosine Kinase
Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer
Applications of Tyrosine Kinase Inhibitor in Cancer Therapy
Global Tyrosine Kinase Inhibitors Market Overview
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline: 411 Drugs
Majority of Cancer Tyrosine Kinase Inhibitors in Preclinical Phase: 164 Drugs
Marketed Cancer Tyrosine Kinase Inhibitors: 32 Drugs
Key Topics Covered:
1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors
2. Tyrosine Kinase: An Overview
3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies
4. Types of Tyrosine Kinase Receptors
5. Signaling Pathway of Receptor Tyrosine Kinase
6. Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer
7. BCR-ABL Tyrosine Kinase Inhibitors
8. Epidermal Growth Factor Receptor Kinase Inhibitors Tyrosine
9. Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
10. Applications of Tyrosine Kinase Inhibitor in Cancer Therapy
11. Global Tyrosine Kinase Inhibitors Market Overview
12. Global Tyrosine Kinase Inhibitor Market Dynamics
13. Global Tyrosine Kinase Inhibitor Market Future Prospects
14. Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase
15. Marketed Cancer Tyrosine Kinase Inhibitors Clinical Insight by Brand Name, Company & Indication
16. Discontinued & Suspended Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company & Phase
17. Competitive Landscape
Companies Mentioned
- AB Science
- Advenchen Laboratories
- Array BioPharma
- ARIAD Pharmaceuticals
- Astellas Pharma (OSI Pharmaceuticals)
- AstraZeneca
- Bayer HealthCare
- Biocad
- Biocon
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celera Genomics Group
- Celgene Corporation (Avila Therapeutics)
- Celltrion
- Chugai Pharmaceutical
- Cytopia Research
- Daiichi Sankyo (Ambit Biosciences Corporation)
- Dyax
- Eisai Co Ltd
- Exelixis
- GlaxoSmithKline
- Hanmi Pharmaceutical
- Novartis
- Onyx Pharmaceuticals
- Pfizer
- Plexxikon
- Reliance Life Sciences
- Roche
- Shire
- Synthon
- Wyeth
- Xcovery
- Zydus Cadila
For more information visit http://www.researchandmarkets.com/research/4q36h3/global_cancer
Media Contact:
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article